Showing results (1-10 of 210) with videos related to
Sort By:
Pageof 21
Seminars in Hematology|March 31, 2019
Can we predict responsiveness to hypomethylating agents in AML?Julia Stomper, Michael LübbertLeukemia|May 7, 2021
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapiesJulia Stomper, John Charles Rotondo, Gabriele Greve, et al.Haematologica|September 2, 2018
Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcomeJulia Stomper, Gabriele Ihorst, Stefan Suciu, et al.Clinical Epigenetics|April 13, 2021
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patientsJulia Stomper, Ruth Meier, Tobias Ma, et al.Cancer|October 5, 2006
Acute myeloid leukemia: epidemiology and etiologyBarbara Deschler, Michael LübbertAnnals of Hematology|April 9, 2008
Current status of epigenetic treatment in myelodysplastic syndromesAndrea Kuendgen, Michael LübbertOncogene|October 7, 2003
Epigenetic targets in hematopoietic malignanciesRainer Claus, Michael LübbertCritical Reviews in Oncology/Hematology|May 12, 2005
DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical resultsWerner Digel, Michael LübbertSeminars in Hematology|July 15, 2005
Decitabine in acute myeloid leukemiaMichael Lübbert, Mark MindenCancer Research|November 18, 2020
Decitabine Induces Gene Derepression on Monosomic Chromosomes: <i>In Vitro</i> and <i>In Vivo</i> Effects in Adverse-Risk Cytogenetics AMLGabriele Greve, Julia Schüler, Björn A Grüning, et al.Pageof 21